Lupin receives CDSCO's approval for anti-allergic drug bepotastine

Lupin Limited has received approval for bepotastine tablets from the Central Drugs Standard Control Organisation (CDSCO) to market the product in India.

Bepotastine is a new second generation antihistamine medicine to be introduced into the Indian pharmaceutical market which could benefit millions of patients suffering from allergic symptoms. It is a rapid acting antihistamine that effectively controls day time and night time triggers of allergic symptoms. Bepotastine is approved by PMDA Japan and is actively marketed in Japan and other South East Asian countries.

The current market for plain antihistamines is estimated to be around Rs 860 crores growing at 14 percent,